Insulin resistance and the endothelium

American Journal of Medicine

Volumn 117, Issue 2, 2004, Pages 109-117

  Hsueh, Willa A ^a   Lyon, Christopher J ^a   Quiñones, Manuel J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; ATENOLOL; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOSARTAN; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; ROSIGLITAZONE; SIMVASTATIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM LESION; EXERCISE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; RENIN-ANGIOTENSIN SYSTEM; THIAZOLIDINEDIONES;

EID: 3242695011     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2004.02.042     Document Type: Review

References (98)

1. Celermajer D.S. Endothelial dysfunction Does it matter? is it reversible? J Am Coll Cardiol. 30:1997;325-333
2. Kintscher U., Wakino S., Kim S., Fleck E., Hsueh W.A., Law R.E. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension. 37:2001;587-593
3. Tummala P.E., Chen X.-L., Sundell C.L., et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature A potential link between the renin-angiotensin system and atherosclerosis. Circulation. 100:1999;1223-1229
4. Chen X.-L., Tummala P.E., Olbrych M.T., Alexander R.W., Medford R.M. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res. 83:1998;952-959
5. Vaughan D.E., Lazos S.A., Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 95:1995;995-1001
6. Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol. 87:2001;10-17
7. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease A unifying hypothesis. Hypertension. 37:2001;1047-1052
8. Dashwood M.R., Tsui J.C.S. Endothelin-1 and atherosclerosis Potential complications associated with endothelin-receptor blockade. Atherosclerosis. 160:2002;297-304
9. Mashimo H., Goyal R.K. Lessons from genetically engineered animal models. IV. Nitric oxide synthase gene knockout mice. Am J Physiol Gastrointest Liver Physiol. 277:1999;G745-G750
10. Swislocki A., Eason T., Kaysen G.A. Oral administration of the nitric oxide biosynthesis inhibitor, L-nitro-arginine methyl ester (L-NAME), causes hypertension, but not glucose intolerance or insulin resistance, in rats. Am J Hypertension. 8:1995;1009-1014
11. Sugiyama F., Haraoka S., Watanabe T., et al. Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab Invest. 76:1997;835-842
12. Daugherty A., Manning M.W., Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 105:2000;1605-1612
13. Daugherty A., Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci. 892:1999;108-118
14. Hayek T., Attias J., Coleman R., et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res. 44:1999;579-587
15. Hsueh W.A., Quinones M.J. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 92:2003;10J-17J
16. Schachinger V., Zeiher A.M. Prognostic implications of endothelial dysfunction Does it mean anything? Coron Artery Dis. 12:2001;435-443
17. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes D.R. Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 101:2000;948-954
18. Hernandez-Pampaloni M., Quiñones M., Chon Y., et al. Endothelial dysfunction is associated with subclinical atherosclerosis in insulin resistant patients. J Nucl Med. 80:2002;140P
19. Fichtlscherer S., Zeiher A.M. Endothelial dysfunction in acute coronary syndromes Association with elevated C-reactive protein levels. Ann Med. 32:2000;515-518
20. Huvers F., De Leeuw P., Houben A., et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes. 48:1999;1300-1307
21. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules Adipocyte-derived plasma protein adiponectin. Circulation. 100:1999;2473-2476
22. Holm T., Aukrust P., Andreassen A.K., et al. Peripheral endothelial dysfunction in heart transplant recipients Possible role of proinflammatory cytokines. Clin Transplant. 14:2000;218-225
23. Hsueh W.A., Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol. 92:2003;3J-9J
24. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 32:(suppl 3):2002;14-23
25. Lyon C.J., Law R.E., Hsueh W.A. Minireview Adiposity, inflammation, and atherogenesis. Endocrinology. 144:2003;2195-2200
26. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
27. Arner P. The adipocyte in insulin resistance Key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 14:2003;137-145
28. Quiñones M.J., Pampaloni M.H., Juarez B.E., et al. Insulin resistance in healthy Mexican-Americans is associated with coronary artery endothelial dysfunction. Diabetes. 49:2000;A146
29. Campisi R., Czernin J., Schoder H., et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation. 98:1998;119-125
30. Balletshofer B.M., Rittig K., Enderle M.D., et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 101:2000;1780-1784
31. Toikka J.O., Ahotupa M., Viikari J.S.A., et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 147:1999;133-138
32. Kita T., Kume N., Minami M., et al. Role of oxidized LDL in atherosclerosis. Ann NY Acad Sci. 947:2001;199-206
33. McIntyre M., Bohr D.F., Dominiczak A.F. Endothelial function in hypertension The role of superoxide anion. Hypertension. 34:1999;539-545
34. Matsuoka H. Endothelial dysfunction associated with oxidative stress in human. Diabetes Res Clin Practice. 54:(suppl):2001;S65-S72
35. Steinberg H.O., Tarshoby M., Monestel R., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 100:1997;1230-1239
36. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 88:2001;10-15
37. Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 68:2000;437-446
38. Yokota T., Oritani K., Takahashi I., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 96:2000;1723-1732
39. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 103:2001;1057-1063
40. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 102:2000;1296-1301
41. Tesfamariam B., Brown M.L., Cohen R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 87:1991;1643-1648
42. Tsunekawa T., Hayashi T., Kano H., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 104:2001;376-379
43. Omori H., Nagashima H., Tsurumi Y., et al. Direct in vivo evidence of a vascular statin A single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol. 54:2002;395-399
44. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307
45. Mancini G.B., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 94:1996;258-265
46. Yusuf S., Gerstein H., Hoogwerf B., et al. Ramipril and the development of diabetes. JAMA. 286:2001;1882-1885
47. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153
48. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) A randomised trial against atenolol. Lancet. 359:2002;995-1003
49. Lindholm L.H., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) A randomised trial against atenolol. Lancet. 359:2002;1004-1010
50. Caballero A.E., Saouaf R., Lim S.C., et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes A placebo-controlled randomized clinical trial. Metabolism. 52:2003;173-180
51. Avena R., Mitchell M.E., Nylen E.S., Curry K.M., Sidawy A.N. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg. 28:1998;1024-1032
52. Quiñones M.J., Hernandez-Pampaloni M., Chon Y., et al. Improvement of coronary artery endothelial dysfunction in insulin resistant patients after treatment with insulin-sensitizing thiazolidinediones. Diabetes. 51:2002;A172
53. Buchanan T., Xiang A., Peters R., et al. Prevention of type 2 diabetes by treatment of insulin resistance Comparison of early vs. late intervention in the TRIPOD study. Diabetes. 51:2002;A35
54. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403
55. Baron A.D., Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 96:1995;786-792
56. Scherrer U., Randin D., Vollenweider P., Vollenweider L., Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 94:1994;2511-2515
57. Shankar R., Wu Y., Shen H., Zhu J., Baron A. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes. 49:2000;684-687
58. Mudaliar S., Henry R.R. New oral therapies for type 2 diabetes mellitus The glitazones or insulin sensitizers. Annu Rev Med. 52:2001;239-257
59. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 18:(suppl 2):2002;S10-S15
60. Maeda N., Takahashi M., Funahashi T., et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50:2001;2094-2099
61. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 129:2000;823-834
62. Loviscach M., Rehman N., Carter L., et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue Relation to insulin action. Diabetologia. 43:2000;304-311
63. Freed M.I., Ratner R., Marcovina S.M., et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 90:2002;947-952
64. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 49:2000;633-639
65. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 86:2001;280-288
66. Day C. Thiazolidinediones A new class of antidiabetic drugs. Diabet Med. 16:1999;179-192
67. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 51:2002;2796-2803
68. Watanabe Y., Sunayama S., Shimada K., et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb. 7:2000;159-163
69. Wakino S., Law R.E., Hsueh W.A. Vascular protective effects by activation of nuclear receptor PPARγ J Diabetes Complications. 16:2002;46-49
70. Zeng G., Nystrom F.H., Ravichandran L.V., et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 101:2000;1539-1545
71. Kuboki K., Jiang Z.Y., Takahara N., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo A specific vascular action of insulin. Circulation. 101:2000;676-681
72. Kim Y.-B., Ciaraldi T.P., Kong A., et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 51:2002;443-448
73. Bagi Z., Koller A., Kaley G. Peroxisome proliferator-activated receptor-γ activation increases NO bioavailability in coronary arterioles in type 2 diabetes by reducing oxidative stress. Am J Physiol Heart Circ Physiol. 286:2004;H742-H748
74. Chan J.R., Boger R.H., Bode-Boger S.M., et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol. 20:2000;1040-1046
75. Stuhlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 287:2002;1420-1426
76. Ichiki T., Takeda K., Tokunou T., et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 21:2001;1896-1901
77. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 273:1998;24266-24271
78. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 101:1998;2711-2719
79. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res. 83:1998;683-690
80. Inoue I., Goto S., Mizotani K., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect Reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 67:2000;863-876
81. Wassmann S., Laufs U., Baumer A.T., et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 37:2001;1450-1457
82. Bellosta S., Ferri N., Arnaboldi L., Bernini F., Paoletti R., Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 23:(suppl 2):2000;B72-B78
83. Huhle G., Abletshauser C., Mayer N., Weidinger G., Harenberg J., Heene D.L. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res. 95:1999;229-234
84. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 103:2001;276-283
85. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 100:1997;2671-2679
86. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82
87. Thompson G.R., Maher V.M., Matthews S., et al. Familial Hypercholesterolaemia Regression Study A randomised trial of low-density-lipoprotein apheresis. Lancet. 345:1995;811-816
88. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131
89. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:2000;1004-1010
90. Ansell B.J., Watson K.E., Weiss R.E., Fonarow G.C. hsCRP and HDL Effects of Statins Trial (CHEST) Rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels a clinical investigation. Heart Dis. 5:2003;2-7
91. Paniagua J.A., Lopez-Miranda J., Escribano A., et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes. 51:2002;2596-2603
92. Costa A., Casamitjana R., Casals E., et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med. 20:2003;743-745
93. Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose Results from the LIPID trial. Diabetes Care. 26:2003;2713-2721
94. Taddei S., Virdis A., Ghiadoni L., Sudano I., Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction Clinical implications. Drugs. 62:2002;265-284
95. McFarlane S.I., Kumar A., Sowers J.R. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 91:2003;30H-37H
96. Duka I., Shenouda S., Johns C., Kintsurashvili E., Gavras I., Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension. 38:2001;1355-1360
97. Campisi R., Nathan L., Pampaloni M.H., et al. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. Circulation. 105:2002;425-430
98. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., Nakamura Y. Rapid communication Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 86:2001;3452-3456